|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song P, Tang W, Tamura S, Hasegawa K,
Sugawara Y, Dong J and Kokudo N: The management of hepatocellular
carcinoma in Asia: A guideline combining quantitative and
qualitative evaluation. Biosci Trends. 4:283–287. 2010.PubMed/NCBI
|
|
3
|
Lee KH, Sung KB, Lee DY, Park SJ, Kim KW
and Yu JS: Transcatheter arterial chemoembolization for
hepatocellular carcinoma: Anatomic and hemodynamic considerations
in the hepatic artery and portal vein. Radiographics. 22:1077–1091.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marelli L, Stigliano R, Triantos C,
Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW
and Burroughs AK: Transarterial therapy for hepatocellular
carcinoma: Which technique is more effective? A systematic review
of cohort and randomized studies. Cardiovasc Interv Radiol.
30:6–25. 2007. View Article : Google Scholar
|
|
6
|
Murata S, Mine T, Ueda T, Nakazawa K,
Onozawa S, Yasui D and Kumita S: Transcatheter arterial
chemoembolization based on hepatic hemodynamics for hepatocellular
carcinoma. ScientificWorldJournal. 2013:4798052013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheung TT, Poon RT, Jenkins CR, Chu FS,
Chok KS, Chan AC, Tsang SH, Dai WC, Yau TC, Chan SC, et al:
Survival analysis of high-intensity focused ultrasound therapy vs.
transarterial chemoembolization for unresectable hepatocellular
carcinomas. Liver Int. 34:e136–e143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhong JH and Li LQ: Postoperative adjuvant
transarterial chemoembolization for participants with
hepatocellular carcinoma: A meta-analysis. Hepatol Res. 40:943–953.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao ZH, Bai DS, Jiang GQ and Jin SJ:
Review of preoperative transarterial chemoembolization for
resectable hepatocellular carcinoma. World J Hepatol. 7:40–43.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lai EC, Lo CM, Fan ST, Liu CL and Wong J:
Postoperative adjuvant chemotherapy after curative resection of
hepatocellular carcinoma: A randomized controlled trial. Arch Surg.
133:183–188. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin CI, Lin ZY, Hsieh MY, Huang CF, Chen
SH and Chuang WL: Potential risk factors for the reactivation of
the replication of hepatitis B and C viruses after transcatheter
arterial chemoembolization of hepatocellular carcinoma. Kaohsiung J
Med Sci. 27:554–559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsieh MY, Lin ZY and Chuang WL: Serial
serum VEGF-A, angiopoietin-2, and endostatin measurements in
cirrhotic patients with hepatocellular carcinoma treated by
transcatheter arterial chemoembolization. Kaohsiung J Med Sci.
27:314–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Zhou J, Fan J, Tan CJ, Qiu SJ, Yu
Y, Huang XW and Tang ZY: Sirolimus inhibits the growth and
metastatic progression of hepatocellular carcinoma. J Cancer Res
Clin Oncol. 135:715–722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY
and Gao DM: Gene expression profiling of fixed tissues identified
hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2
as biomarkers of lymph node metastasis in hepatocellular carcinoma.
Clin Cancer Res. 17:5463–5472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu
MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, et al: Role of overexpression of
CD151 and/or c-Met in predicting prognosis of hepatocellular
carcinoma. Hepatology. 49:491–503. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kwon MJ, Seo J, Kim YJ, Kwon MJ, Choi JY,
Kim TE, Lee DH, Park S, Shin YK, Han J and Choi YL: Prognostic
significance of CD151 overexpression in non-small cell lung cancer.
Lung Cancer. 81:109–116. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hashida H, Takabayashi A, Tokuhara T,
Hattori N, Taki T, Hasegawa H, Satoh S, Kobayashi N, Yamaoka Y and
Miyake M: Clinical significance of transmembrane 4 superfamily in
colon cancer. Br J Cancer. 89:158–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang YM, Zhang ZW, Liu QM, Sun YF, Yu JR
and Xu WX: Overexpression of CD151 predicts prognosis in patients
with resected gastric cancer. PLoS One. 8:e589902013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Palmer TD, Martínez CH, Vasquez C, Hebron
KE, Jones-Paris C, Arnold SA, Chan SM, Chalasani V, Gomez-Lemus JA,
Williams AK, et al: Integrin-free tetraspanin CD151 can inhibit
tumor cell motility upon clustering and is a clinical indicator of
prostate cancer progression. Cancer Res. 74:173–187. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu X, Chen W, Zhang L, Miao R, Zhou Y, Wan
Y, Dong Y and Liu C: Prognostic significance of neutrophil to
lymphocyte ratio in patients with hepatocellular carcinoma after
transcatheter arterial chemoembolization. Chin Med J (Engl).
127:4204–4209. 2014.PubMed/NCBI
|
|
21
|
Li X, Chen ZH, Xing YF, Wang TT, Wu DH,
Wen JY, Chen J, Lin Q, Dong M, Wei L, et al: Platelet-to-lymphocyte
ratio acts as a prognostic factor for patients with advanced
hepatocellular carcinoma. Tumor Biol. 36:2263–2269. 2015.
View Article : Google Scholar
|
|
22
|
Lee CH, Lin YJ, Lin CC, Yen CL, Shen CH,
Chang CJ and Hsieh SY: Pretreatment platelet count early predicts
extrahepatic metastasis of human hepatoma. Liver Int. 35:2327–2336.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shuster A, Huynh TJ, Rajan DK, Marquez MA,
Grant DR, Huynh DC and Jaskolka JD: Response evaluation criteria in
solid tumors (RECIST) criteria are superior to European Association
for Study of the Liver (EASL) criteria at 1 month follow-up for
predicting long-term survival in patients treated with
transarterial chemoembolization before liver transplantation for
hepatocellular cancer. J Vasc Interv Radiol. 24:805–812. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ashman LK, Aylett GW, Mehrabani PA,
Bendall LJ, Niutta S, Cambareri AC, Cole SR and Berndt MC: The
murine monoclonal antibody, 14A2.H1, identifies a novel platelet
surface antigen. Br J Haematol. 79:263–270. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hasegawa H, Watanabe H, Nomura T,
Utsunomiya Y, Yanagisawa K and Fujita S: Molecular cloning and
expression of mouse homologue of SFA-1/PETA-3 (CD151), a member of
the transmembrane 4 superfamily. Biochim Biophys Acta.
1353:125–130. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hasegawa H, Kishimoto K, Yanagisawa K,
Terasaki H, Shimadzu M and Fujita S: Assignment of SFA-1 (PETA-3),
a member of the transmembrane 4 superfamily, to human chromosome
11p15.5 by fluorescence in situ hybridization. Genomics.
40:193–196. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nicole Johnson and Susan B Wormsley: Human
leukocyte differentiation antigens of the sixth international
workshop: What can we expect to see in the clinic? Clinical
Immunology Newsletter. 18:33–42. 1998. View Article : Google Scholar
|
|
29
|
Sincock PM, Mayrhofer G and Ashman LK:
Localization of the transmembrane 4 superfamily (TM4SF) member
PETA-3 (CD151) in normal human tissues: Comparison with CD9, CD63,
and alpha5beta1 integrin. J Histochem Cytochem. 45:515–525. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sadej R, Grudowska A, Turczyk L, Kordek R
and Romanska HM: CD151 in cancer progression and metastasis: A
complex scenario. Lab Invest. 94:41–51. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu M, Guo J, Xia H, Li W, Lu Y, Dong X,
Chen Y, Xie X, Fu S and Li M: Alpha-fetoprotein activates AKT/mTOR
signaling to promote CXCR4 expression and migration of hepatoma
cells. Oncoscience. 2:59–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shi GM, Ke AW, Zhou J, Wang XY, Xu Y, Ding
ZB, Devbhandari RP, Huang XY, Qiu SJ, Shi YH, et al: CD151
modulates expression of matrix metalloproteinase 9 and promotes
neoangiogenesis and progression of hepatocellular carcinoma.
Hepatology. 52:183–196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fei Y, Wang J, Liu W, Zuo H, Qin J, Wang
D, Zeng H and Liu Z: CD151 promotes cancer cell metastasis via
integrins α3β1 and α6β1 in vitro. Mol Med Rep. 6:1226–1230. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ke AW, Shi GM, Zhou J, Huang XY, Shi YH,
Ding ZB, Wang XY, Devbhandari RP and Fan J: CD151 amplifies
signaling by integrin α6β1 to PI3K and induces the
epithelial-mesenchymal transition in HCC cells. Gastroenterology.
140:1629–1641.e15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jia ZZ, Jiang GM and Feng YL: Serum
HIF-1alpha and VEGF levels pre- and post-TACE in patients with
primary liver cancer. Chin Med Sci J. 26:158–162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cillo U, Vitale A, Grigoletto F, Farinati
F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, et
al: Prospective validation of the Barcelona clinic liver cancer
staging system. J Hepatol. 44:723–731. 2006. View Article : Google Scholar : PubMed/NCBI
|
